NCT03737643 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT03737643
Title	Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O)
Acronym	DUO-O
Recruitment	Active, not recruiting
Gender	female
Phase	Phase III
Variant Requirements	No
Sponsors	AstraZeneca
Indications	fallopian tube cancer peritoneum cancer ovary serous adenocarcinoma endometrioid ovary carcinoma ovarian clear cell carcinoma ovarian carcinosarcoma
Therapies	Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Durvalumab + Paclitaxel Bevacizumab + Durvalumab + Olaparib Olaparib Bevacizumab + Durvalumab
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| ROU \| POL \| ITA \| HUN \| FRA \| FIN \| ESP \| DNK \| DEU \| CAN \| BRA \| BGR \| BEL \| AUT

No variant requirements are available.